
Astellas And Pfizer's XTANDITM (Enzalutamide) Shows Long-Term Overall Survival In Metastatic Hormone-Sensitive Prostate ...
(MENAFN- PR Newswire) Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus …